Famotidine (Pepcid) is an antihistamine that inhibits the H-2 histamine receptors in the stomach inhibiting acid secretion. It is used in the treatment and prevention of heartburn and peptic ulcer disease.

Famotidine Uses:

• Oral:

  • Gastroesophageal reflux disease:

    • Treatment of gastroesophageal reflux disease (GERD) and esophagitis secondary to GERD.

  • Heartburn (OTC only):

    • heartburn, acid indigestion, and sour stomach.

  • Peptic ulcer disease:

    • Treatment of active duodenal or gastric ulcers.

Note: Even though a labeled indication, proton pump inhibitors (PPIs) are considered the standard of care for treatment of peptic ulcer disease (PUD) rather than H-2-receptor antagonists (eg, famotidine) (Lanas 2017; Vakil 2019).

• Injection:

  • Patients not able to take oral medication:

    • For patients who cannot take orally

  • Off-Label Use of Famotidine in Adults:

    • Aspiration prophylaxis in patients undergoing anesthesia
    • Chronic spontaneous urticaria
    • Infusion reaction, premedication
    • Mastocytosis
    • Stress ulcer prophylaxis in select critically ill patients

Famotidine (Pepcid) Dose in Adults

Famotidine (Pepcid) Dose in the Aspiration prophylaxis in patients undergoing anesthesia (off-label):

Note: can be used in patients high risk for aspiration:

• IV: 20 mg as a single dose ~40 to 60 minutes before inducing anesthesia;
• It can be combined with rapid-acting nonparticulate antacid (eg, oral sodium citrate and citric acid) and/or metoclopramide.

Famotidine (Pepcid) Dose in the treatment of chronic spontaneous urticaria as an alternative agent (adjunct) (off-label):

Note: Used as an adjunct if poor response to full-dose H-1 antihistamine.

• Oral: 20 mg twice daily combined with H-1 antihistamine;
• Wait for 2 to 4 weeks to measure the appropriate response.

Famotidine (Pepcid) Dose in the treatment of Gastroesophageal reflux disease:

• Initial therapy:

  • Mild and intermittent symptoms (<2 episodes/week), and no evidence of erosive esophagitis:

Note: For much serious or recurring initial symptoms, with or without proof of erosive esophagitis, a proton pump inhibitor (PPI) as initial therapy is recommended.

• Oral: 10 mg twice daily as needed; if symptoms persist after 2 to 4 weeks, increase to 20 mg twice daily for 2 weeks; if symptoms improve, may continue therapy as needed.

Note: If symptoms persist after 2 weeks of 20 mg twice daily, discontinue and consider PPI therapy.

Famotidine (Pepcid) Dose in the treatment of Residual acid reflux symptoms despite maximal PPI therapy (adjunct):

• Oral: 20 mg one time each day given before sleep in addition to PPI therapy.
• The dose may also be administered intermittently or on-demand with scheduled PPI.

• OTC labeling (patient-guided therapy):

  • Heartburn, mild intermittent symptoms: Oral: 10 to 20 mg up to two times a day when needed (maximum: 40 mg/day); may also be taken 10 to 60 minutes before meals or drinks that initiate heartburn (maximum: 40 mg/day).

Famotidine (Pepcid) Dose for premedication in Infusion reactions (adjunct) (off-label):

• IV, Oral: 20 mg usually administered 30 to 60 minutes prior to infusion of certain chemotherapy agents or biologics;
• It is mostly given in combination with an H-1 antihistamine (eg, diphenhydramine) and glucocorticoid (refer to institutional protocols).

Famotidine (Pepcid) Dose in the treatment of Mastocytosis (adjunct):

• Oral: 10 to 20 mg every 12 hours modified to attain GI symptom relief.
• Typically consumed with other appropriate agents (eg, H-1 antihistamine and/or leukotriene inhibitor).

Famotidine (Pepcid) Dose for Stress ulcer prophylaxis in selected critically ill patients:

Note: For ICU patients with linked risk factors for GI bleeding (including coagulopathy, mechanical ventilation for >48 hours, traumatic brain injury, history of GI ulceration or bleeding within the past year, extensive burns); suspend prophylaxis when the risk factors are resolved.

• Oral or via nasogastric (NG) tube (alternative to enteral PPI):
  • 20 mg twice a day.
• IV:
  • 20 mg twice a day.

Famotidine (Pepcid) Dose in Childrens

Famotidine (Pepcid) Dose in the treatment of GERD:

• Oral:

  • Suspension:

    • Infants <3 months:
      • 0.5 mg/kg/dose one time each day for up to 8 weeks;
      • If not effective after 2 weeks, increase the dose to 1 mg/kg/dose one time a day is suggested.
    • Infants ≥3 months, Children, and Adolescents ≤16 years:
      • Initial: 0.5 mg/kg/dose two times a day;
      • The maximum dose is 40 mg/dose;
      • Doses up to 1 mg/kg/dose two times a day have been reported.

  • Tablets:

    • Children and Adolescents ≥40 kg:
      • 20 mg twice a day for up to 6 weeks;
      • For esophagitis and additional symptoms due to GERD, may use 20 to 40 mg twice a day for up to 12 weeks

• IV:

  • Infants <3 months:
    • 0.25 mg/kg/dose once each day;
    • The dose based on a pharmacokinetic study that included 7 patients <3 months who were given IV famotidine.
  • Infants ≥3 months:
    •  Initial: 0.25 mg/kg/dose every 12 hours;
    • The maximum dose is 20 mg/dose;
    • The dose is based on a pharmacokinetic study that included 11 patients >3 to 12 months who received IV famotidine.
  • Children and Adolescents:
    • Initial: 0.25 mg/kg/dose every 12 hours;
    • The maximum dose: 20 mg/dose;
    • Doses up to 0.5 mg/kg/dose every 12 hours have been reported

Famotidine (Pepcid) Dose in the treatment of Heartburn, acid indigestion, or sour stomach (OTC labeling):

• Children ≥12 years and Adolescents:

  • Oral: 10 to 20 mg after every 12 hours;
  • The dose can be taken 15 to 60 minutes before eating food that causes heartburn;
  • The maximum daily dose is 2 tablets/day (20 to 40 mg dependent upon OTC product)

Famotidine (Pepcid) Dose in the treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison):

• Adolescents ≥17 years:

  • Oral: Initial: 20 mg every 6 hours, may increase up to 160 mg every 6 hours
  • IV: 20 mg every 12 hours

Famotidine (Pepcid) Dose in the treatment of Peptic ulcer disease:

• Oral:

  • Suspension: Children and Adolescents ≤16 years:
    • 0.5 mg/kg/day before sleeping or divided twice each day;
    • The maximum daily dose is 40 mg/day;
    • Doses up to 1 mg/kg/day at bedtime or distributed twice daily have been consumed.

• Tablets:

  • Children and Adolescents >40 kg:

    • Duodenal ulcer: Acute therapy: 40 mg once a day before sleep or 20 mg two times daily for 4 to 8 weeks
    • Gastric ulcer: Acute therapy: 40 mg once a day at bedtime for up to 8 weeks

• IV:

  • Children and Adolescents:
    • Initial: 0.25 mg/kg/dose every 12 hours;
    • The maximum dose: 20 mg/dose;
    • Doses up to 0.5 mg/kg/dose every 12 hours is reported

Famotidine (Pepcid) Dose for the prophylaxis of stress ulcers, gastric acid suppression:

• Infants, Children, and Adolescents:

  • IV: 1 to 2 mg/kg/day in divided doses every 8 to 12 hours;
  • The maximum daily dose is 40 mg/day.

Famotidine Pregnancy Risk Category: B

• Famotidine passes the placental barrier.
• The renal clearance of famotidine may be affected by pregnancy-related physiological changes.
• Histamine H antagonists were evaluated for the treatment and prevention of gastroesophageal acid disease (GERD), in pregnancy.
• For initial therapy, agents other than famotidine might be preferred.
• For aspiration prophylaxis, you can take histamine H antagonists before a cesarean birth.

Famotidine use during breastfeeding:

• Breast milk contains Famotidine.
• When famotidine was compared to a therapeutic infant dose of 0.5 mg/kg/day, the relative infant dose (RID), of 2.2% was determined. This is based on the peak breastmilk concentration.
• When the RID of the medication is less than 10%, breastfeeding can be considered satisfactory.
• The RID of Famotidine was determined using a milk content of 0.072 mg/mL. This gives an estimated daily infant dose via breastmilk of 0.011 mg/kg/day.
• The mother administered a single dose orally of 40 mg famotidine to her milk.
• According to the manufacturer breastfeeding should be considered during therapy.
• One must consider the risks of infant exposure as well as the benefits to the mother from breastfeeding.
• Famotidine is a preferred agent when treatment with a histamine H antagonist must be done. This is due to the lower concentrations of famotidine in breast milk.

Famotidine (Pepcid) Dose in Kidney Disease:

• Injection:

  • CrCl ≥50 mL/minute: No dosage adjustment required.
  • CrCl <50 mL/minute: Administer 50% of dose or increase the interval to every 36 to 48 hours.

• Oral:

  • Active duodenal ulcer:

    • CrCl 30 to 60 mL/minute: Maximum dose: 20 mg one time daily or 40 mg every other day.
    • CrCl <30 mL/minute: Maximum dose: 20 mg on alternate day or 10 mg once a day.

  • Maintenance of duodenal ulcer:

    • CrCl 30 to 60 mL/minute: Maximum dose: 20 mg on alternate day or 10 mg once daily
    • CrCl <30 mL/minute: Maximum dose: 10 mg every other day

  • Gastric ulcer:

    • CrCl 30 to 60 mL/minute: Maximum dose: 20 mg once each day or 40 mg on alternate day
    • CrCl <30 mL/minute: Maximum dose: 20 mg every other day or 10 mg once daily

  • GERD:

    • Esophagitis and accompanying symptoms due to GERD:
      • CrCl 30 to 60 mL/minute:
        • The maximum dose for the 20 mg twice-daily regimen: 20 mg once daily or 40 mg every alternate day
        • The maximum dose for the 40 mg twice-daily regimen: 40 mg once every day
      • CrCl <30 mL/minute:
        • The maximum dose for the 20 mg twice-daily regimen: 20 mg every other day or 10 mg once a day
        • The maximum dose for the 40 mg two times in daily routine: 20 mg one time a day
    • Treatment of GERD (short-term):
      • • CrCl 30 to 60 mL/minute: Maximum dose: 20 mg one time a day
        • CrCl <30 mL/minute: Maximum dose: 20 mg on alternate day or 10 mg once a day
    • Pathological hypersecretory conditions: Avoid use

Dose in Liver Disease:

There are no dosage adjustments given in the manufacturer's labeling.

---

All reported adverse drug reactions are for the oral formulations unless otherwise noted.

Common Side Effects of Famotidine (Pepcid):

• Central nervous system:

  • Agitation

Less Common Side Effects of Famotidine (Pepcid):

• Central nervous system:

  • Headache
  • Dizziness

• Gastrointestinal:

  • Diarrhea
  • Constipation
  • Necrotizing enterocolitis

• Local:

  • Irritation at the injection site

Contraindications to Famotidine Include:

Severe hypersensitivity (eg anaphylaxis), to famotidine or other H-2 antagonists or any component of this formulation.

OTC labeling

• Use OTC for self-medication. Do not use OTC if you experience difficulty or pain while ingesting food, nausea, vomiting, bloody or black stool.
• Other acid reducers may cause allergic reactions
• Renal impairment
• Coadministration with acid reducers

Warnings and precautions

• ECG changes

  • Patients with mild-to-severe renal impairment have been reported to experience prolonged QT intervals. 
  • FDA received reports about torsades-de-pointes that were caused by famotidine.

• Vitamin B 12 deficiency:

  • Long-term treatment (>=2 year) can lead to vitamin B12 malabsorption and then vitamin B12 deficiency.
  • The severity of the deficiency depends on the dose. It is more severe in women than in men (30 years). Prevalence decreases after stopping therapy.

• Gastric cancer:

  • The presence of gastric cancer is not exempted from treatment.

• Renal impairment

  • Take caution; there is a greater risk of CNS adverse effects and QT prolongation.
  • Dosage adjustment is recommended for mild and chronic renal impairment (CrCl =60mL/minute).

Famotidine: Drug Interaction

Note: Drug Interaction Categories:

• Risk Factor C: Monitor When Using Combination
• Risk Factor D: Consider Treatment Modification
• Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy)
Cefpodoxime	Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.
Cysteamine (Systemic)	Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic).
Dexmethylphenidate	Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.
Erdafitinib	May increase the serum concentration of OCT2 Substrates.
Fosamprenavir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.
Indinavir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir.
Iron Salts	Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. Exceptions: Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.
Methylphenidate	Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.
Multivitamins/Minerals (with ADEK, Folate, Iron)	Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.
Nelfinavir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.
Saquinavir	Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir.
Varenicline	Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.
Velpatasvir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir.
Risk Factor D (Consider therapy modification)
Acalabrutinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib. Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.
Atazanavir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir. Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.
Bosutinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib. Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.
Cefditoren	Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Dacomitinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Dacomitinib. Management: Administer dacomitinib at least 6 hours before or 10 hours after an histamine H2-receptor antagonist (H2RA).
Erlotinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib. Management: Avoid H2-antagonists in patients receiving erlotinib when possible. If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.
Gefitinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib. Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.
Itraconazole	Histamine H2 Receptor Antagonists may increase the serum concentration of Itraconazole. Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole. Management: Administer Sporanox brand itraconazole at least 2 hours before or 2 hours after administration of any histamine H2 receptor antagonists (H2RAs). Exposure to Tolsura brand itraconazole may be increased by (H2RAs); consider itraconazole dose reduction.
Ketoconazole (Systemic)	Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist. Monitor patients closely for signs of inadequate clinical response to ketoconazole.
Ledipasvir	Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir.
Mesalamine	Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.
Nilotinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib. Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.
Posaconazole	Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole. Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.
Rilpivirine	Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine. Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.
Secretin	Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyper-response in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma. Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.
Tafenoquine	May increase the serum concentration of OCT2 Substrates. Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.
Risk Factor X (Avoid combination)
Cefuroxime	Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.
Dasatinib	Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.
Delavirdine	Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine. Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine. The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.
Neratinib	Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. Management: Administer neratinib at least 2 hours before or 10 hours after administration of a histamine H2 receptor antagonist to minimize the impact of this interaction.
PAZOPanib	Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. Management: Avoid the use of histamine H2-antagonists in combination with pazopanib. Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.
Risedronate	Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.

Monitoring parameters:

• CBC,
• gastric pH,
• Occult blood with GI bleeding

How to administer Famotidine (Pepcid)?

IV push:

• Administer over at least 2 minutes.

Solution for infusion:

• Administer over 15 to 30 minutes.

Oral:

• Administer without regard to meals. May administer with antacids.

Suspension:

• Shake vigorously before use.

Tablet (OTC):

• Do not chew.
• To prevent symptoms, administer 10 to 60 minutes before eating food or drinking beverages known to cause heartburn.

Mechanism of action of Famotidine (Pepcid):

It inhibits competitively histamine at H-1 receptors in the gastric parietal cell cells. This inhibits gastric acid production.

The onset of action when orally administered: Antisecretory effect:

• Within 1 hour

Peak antisecretory effect:

• Oral: Within 1 to 3 hours (dose-dependent);
• IV: Within 30 minutes

The duration of its antisecretory effect:

• IV, Oral: 10 to 12 hours

Absorption when administered orally:

• Incompletely absorbed

Protein binding:

• 15% to 20%

Metabolism:

• 30% to 35%;
• It has minimal first-pass metabolism and forms one metabolite (S-oxide)

Bioavailability when administered orally:

• 40% to 45%

Half-life elimination:

• IV:
  • Infants: ≤3 months: 8.1 ± 3.5 hours to 10.5 ± 5.4 hours;
  • Infants >3 to 12 months: 4.5 ± 1.1 hours
  • Children <11 years: 3.38 ± 2.6 hours
  • Children ≥11 years and Adolescents ≤15 years: 2.3 ± 0.4 hours
  • Adults: 2.5 to 3.5 hours;
  • The half-life is prolonged with renal impairment;
    • Oliguria: >20 hours;
    • Anuria: 24 hours

Time to peak, serum:

• Oral: About 1 to 3 hours

Excretion:

• Urine (25% to 30% when administered orally, 65% to 70% when administered IV as unchanged drug).

International Brand Names of Famotidine:

• Acid Controller Max St
• Acid Controller Original Str
• Acid Reducer Maximum Strength
• Acid Reducer
• Heartburn Relief Max St
• Heartburn Relief
• Pepcid
• Pepcid AC Maximum Strength
• ALTI-Famotidine
• APO-Famotidine
• BCI-Famotidine
• CO Famotidine
• Famotidine Omega W-O Preserv
• Famotidine Omega W-Preserv
• GMD-Famotidine
• MYLAN-Famotidine
• NTP-Famotidine
• TEVA-Famotidine
• Acifam
• Androtin
• Antiflam
• Antodine
• Aulzadin
• Ausfam
• Bestidine
• Corocyd
• Denufam
• Durater
• Facid
• Facidex
• Fadin
• Fadine
• Fadul
• Famagen
• Famatel
• Famo
• Famoc
• Famocid
• Famodar
• Famodil
• Famodin
• Famodine
• Famogal
• Famogard
• Famonerton
• Famopsin
• Famosan
• Famosia
• Famotaz
• Famotec
• Famotid
• Famotin
• Famowal
• Famox
• Famozol
• Faradin
• Farotin
• Ferotine
• Fibonel
• Fudone
• Fuweidin
• Gasafe
• Gasmodin
• Gaster
• Gastren
• Gastridin
• Gastril
• Gastrium
• Gastro
• Gastrodomina
• Gastrum
• H2 Bloc
• Hista-Bloc
• Interfam
• Keamotin
• Kimodin
• Logos
• Ludex
• Modin
• Motiax
• Motidin
• Navatac
• Nulcerin
• Nulcex
• Pamacid
• Pepcid
• Pepcid AC
• Pepcidac
• Pepcidin
• Pepcidina
• Pepcidine
• Pepdif
• Pepdine
• Pepfamin
• Peptifam
• Peptoci
• Pepzan
• Pharmotidine
• Quamatel
• Quamtel
• Sedanium-R
• Snow
• Stadin
• Stomax
• Supertidine
• Tarpan
• Tismafam
• Topcid
• Ulcatif
• Ulcelac
• Ulcenol
• Ulceran
• Ulfadin
• Ulfagel
• Ulfamid
• Ulmo
• Vesmo-20
• Voker
• Weimok
• Winiful
• Yamadin

Famotidine Brand Names in Pakistan:

Famotidine Injection 20 Mg in Pakistan
Pepgen	Fassgen Pharmaceuticals

 

Famotidine Injection 40 Mg in Pakistan
Famot-40	Shaigan Pharmaceuticals (Pvt) Ltd

 

Famotidine Syrup 10 Mg in Pakistan
Famgic	Goodman Laboratories

 

Famotidine Syrup 10 Mg/5ml in Pakistan
Apsin	Saffron Pharmaceutical Company

 

Famotidine Suspension 10 Mg in Pakistan
Famoday	Max Pharmaceuticals
Maripep	Miracle Pharmaceuticals(Pvt) Ltd

 

Famotidine Suspension 10 Mg/5ml in Pakistan
Acicon	Barrett Hodgson Pakistan (Pvt) Ltd.
Acicon	Barrett Hodgson Pakistan (Pvt) Ltd.
Acidrol	Medisearch Pharmacal(Pvt) Ltd
Cantil	Helicon Pharmaceutek Pakistan (Pvt) Ltd.
Capcid	Olive Laboratories
Fadiphine	Global Pharmaceuticals
Fagastril	Gray`S Pharmaceuticals
Fam Ph	Evergreen Pharmaceuticals Pvt Limited
Fambria	Ambrosia Pharmaceuticals
Famcare	Care Pharmaceuticals
Famdin	Pakistan Pharmaceutical Products (Pvt) Ltd.
Famo Rains	Mac & Rans Pharmaceuticals (Pvt) Ltd
Famobex	Cibex (Private) Limited
Famorax	Mediceena Pharma (Pvt) Ltd.
Famoscot	Scotmann Pharmaceuticals
Famot	Shaigan Pharmaceuticals (Pvt) Ltd
Famotidine	Lawrence Pharma
Famron	P.D.H. Pharmaceuticals (Pvt) Ltd.
Famtac	Rasco Pharma
Famtaza	Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Fastine	Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Fedcid	Fedro Pharmaceutical
Femas	Pearl Pharmaceuticals
Fomen	Shrooq Pharmaceuticals
G-Met	Tabros Pharma
Gastridine	Tg Pharma
Gepep	Akson Pharmaceuticals (Pvt) Ltd.
Gimed	Albro Pharma
Jevity	Wilshire Laboratories (Pvt) Ltd.
Kamcid	Bloom Pharmaceuticals (Pvt) Ltd.
Loacid	Raazee Theraputics (Pvt) Ltd.
Neofam	Neo Medix
Neutidin	Neutro Pharma (Pvt) Ltd.
Nogacid	Lowitt Pharmaceuticals (Pvt) Ltd
Pepcimed	Medicraft Pharmaceuticals (Pvt) Ltd.
Pepdine	Lotus Pharmaceuticals (Pvt) Ltd
Peptiban	Werrick Pharmaceuticals
Pharmotidine	Epharm Laboratories
Polypep	Wilsons Pharmaceuticals
Recid	Regent Laboratories Ltd.
Reducid	Platinum Pharmaceuticals (Pvt.) Ltd.
Servipep	Polyfine Chempharma (Pvt) Ltd.
Ulcenil	Siza International (Pvt) Ltd.

 

Famotidine Suspension 40 Mg/5ml in Pakistan
Zepsin	Cirin Pharmaceuticals (Pvt) Ltd.

 

Famotidine Tablets 10 Mg in Pakistan
Bepsin	Benson Pharamceuticals.
Chewfam	Atco Laboratories Limited
Femme	Batala Pharmaceuticals.
Fomicid	Himont Pharmaceuticals (Pvt) Ltd.
Hiler	Muller & Phipps Pakistan (Pvt) Ltd.
Nobar Chewable	Caylex Pharmaceuticals (Pvt) Ltd.
Peptiban	Werrick Pharmaceuticals
Peptiban-Ac	Werrick Pharmaceuticals
Reducid	Platinum Pharmaceuticals (Pvt.) Ltd.
U-Fit	Panacea Pharmaceuticals

 

Famotidine Tablets 20 Mg in Pakistan
Acicon	Barrett Hodgson Pakistan (Pvt) Ltd.
Afomit	Alliance Pharmaceuticals (Pvt) Ltd.
Altad	Alson Pharmaceuticals
Apsin	Saffron Pharmaceutical Company
Ardfame	Ardin Pharmaceuticals
Atodine	Macquins International
Basil	Sycom Pharmaceuticals
Bepsin	Benson Pharamceuticals.
Brimdin	Rasco Pharma
Cantil	Helicon Pharmaceutek Pakistan (Pvt) Ltd.
Capcid	Olive Laboratories
Concid	Reko Pharmacal (Pvt) Ltd.
Curofam	Mega Pharmaceuticals (Pvt) Ltd
Ducid	Glaxosmithkline
Facid	Shafaz Pharma International (Pvt) Ltd.
Fadiphine	Global Pharmaceuticals
Fagastril	Gray`S Pharmaceuticals
Famcidine	Webros Pharmaceuticals
Famdin	Pakistan Pharmaceutical Products (Pvt) Ltd.
Famid	Wilshire Laboratories (Pvt) Ltd.
Famitine	Efroze Chemical Industries (Pvt) Ltd.
Famobex	Cibex (Private) Limited
Famocin	Navegal Laboratories
Famodin	Drugs Inn Pakistan
Famodine	Neutro Pharma (Pvt) Ltd.
Famogen	Genera Pharmaceuticals
Famonon	Dr. Raza Pharma (Private) Limited
Famopep	Royal Consumer Manufacturing Company
Famopsin	High - Q International
Famorjine	Adfa San Pharmaceuticals.
Famoscot	Scotmann Pharmaceuticals
Famosib	Irza Pharma (Pvt) Ltd.
Famot-20	Shaigan Pharmaceuticals (Pvt) Ltd
Famotop	Xenon Pharmaceuticals (Pvt) Ltd.
Famron	P.D.H. Pharmaceuticals (Pvt) Ltd.
Famtab	Zanctok Pharmaceuticals
Famtaza	Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Famtine	Efroze Chemical Industries (Pvt) Ltd.
Famulcer	Swiss Pharmaceuticals (Pvt) Ltd.
Famus	Biogen Pharma
Fanitin	Europak Pharma (Pvt) Ltd
Fastine	Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Femas	Pearl Pharmaceuticals
Femme	Batala Pharmaceuticals.
Femoceran	Alina Combine Pharmaceuticals (Pvt) Ltd.
Femoceran	Alina Combine Pharmaceuticals (Pvt) Ltd.
Femodine	Neutro Pharma (Pvt) Ltd.
Fencid	Pharmacare Laboratories (Pvt) Ltd.
Flodin	Flow Pharmaceuticals (Pvt) Ltd.
Fm 20	Hizat Pharmaceutical Industries (Pvt) Ltd.
Fomen	Shrooq Pharmaceuticals
Fomicid	Himont Pharmaceuticals (Pvt) Ltd.
Gaster	Hamaz Pharmaceutical (Pvt) Ltd.
Gastoch	Usawa Pharmaceuticals
Gastridine	Tg Pharma
Gimed	Albro Pharma
H2-Foz	Fozan Pharmaceuticals Industriers (Pvt) Ltd
H2bf	Rakaposhi Pharmaceutical (Pvt) Ltd.
H2bf	Rakaposhi Pharmaceutical (Pvt) Ltd.
H2f	Ferozsons Laboratoies Ltd.
Hepsin	Heal Pharmaceuticals Pvt Ltd
Hiler	Muller & Phipps Pakistan (Pvt) Ltd.
Hycocid	Bloom Pharmaceuticals (Pvt) Ltd.
Ispep	Medisure Laboratories Pakistan (Pvt.) Ltd.
Jevity	Wilshire Laboratories (Pvt) Ltd.
Jevity	Wilshire Laboratories (Pvt) Ltd.
Kalfot	Medera Pharmaceuticals (Pvt) Ltd.
Ketacid	Hygeia Pharmaceuticals
Kotidine	Al-Habib Pharmaceuticals.
Lyofam	Valor Pharmaceuticals
Mot	Jaens Pharma
Motn	Caraway Pharmaceuticals
Nencid	Nenza Pharmaceuticals (Pvt) Limited
Neofam	Neo Medix
No-Acid	Nova Med Pharmaceuticals
Nobar	Caylex Pharmaceuticals (Pvt) Ltd.
Nocer	Bryon Pharmaceuticals (Pvt) Ltd.
Nocid	Novartis Pharma (Pak) Ltd
Nogacid	Lowitt Pharmaceuticals (Pvt) Ltd
Novifam	Novins International
Optifam	Merck Private Ltd.
Panalba	R.Y. International
Pandona	Venture Chemical & Pharmaceuticals (Pvt) Ltd.
Pepcimed	Medicraft Pharmaceuticals (Pvt) Ltd.
Pepdine	Lotus Pharmaceuticals (Pvt) Ltd
Pepfin	Innvotek Pharmaceuticals
Pepgard	Elko Organization (Pvt) Ltd.
Pepmon	Shaheen Agencies
Peprax	Umersons
Peprid	Helix Pharma (Private) Limited
Peptiban	Werrick Pharmaceuticals
Peptiban Dispersible	Werrick Pharmaceuticals
Peptiloc	Bosch Pharmaceuticals (Pvt) Ltd.
Pitfam	Jinnah Pharmaceuticals
Polypep	Wilsons Pharmaceuticals
Prilosec	Aries Pharmaceuticals (Pvt) Ltd
Qincid	Qintar Pharmacuticals
Quamatel	Medimpex Scientific Office
Reducid	Platinum Pharmaceuticals (Pvt.) Ltd.
Ricer	Polyfine Chempharma (Pvt) Ltd.
So-Fem	Roryan Pharmaceutical Industries (Pvt) Ltd
Surfac	Meditech Pharmaceuticals
Tabrodine	Tabros Pharma
Tinopep	Remington Pharmaceutical Industries (Pvt) Ltd.
Tulip	Tagma Pharma (Pvt) Ltd.
U-Fit	Panacea Pharmaceuticals
Ul-Safe	Saydon Pharmaceutical Industries (Pvt) Ltd.
Ulcemal	Atco Laboratories Limited
Ulcenil	Siza International (Pvt) Ltd.
Ulcepep-20	Epoch Pharmaceutical
Ulcepep-20	Epoch Pharmaceutical
Ulciban	Star Laboratories (Pvt) Ltd.
Ulcofin	Pharmix Laboratories (Private) Limited.
Ulfam	Highnoon Laboratories Ltd.
Ulfarid	Davis Pharmaceutical Laboratories
Ulsin	Don Valley Pharmaceuticals (Pvt) Ltd.
Vefam	Vega Pharmaceuticals Ltd.
Volvic	Rotex Medica Pakistan (Pvt) Ltd
Welfam	Ferroza International Pharmaceuticals (Pvt) Ltd.
Welfam	Ferroza International Pharmaceuticals (Pvt) Ltd.
Yamadin	Bex Pharma (Pvt) Ltd.
Zebid	Atco Laboratories Limited
Zepsin	Cirin Pharmaceuticals (Pvt) Ltd.

 

Famotidine Tablets 40 Mg in Pakistan
Acicon	Barrett Hodgson Pakistan (Pvt) Ltd.
Afomit	Alliance Pharmaceuticals (Pvt) Ltd.
Aladin	Bio Pharma
Altad	Alson Pharmaceuticals
Apsin	Saffron Pharmaceutical Company
Ardfame	Ardin Pharmaceuticals
Atodine	Macquins International
Ban-Ulcer	Pakheim Internanational Pharma
Basil	Sycom Pharmaceuticals
Bepsin	Benson Pharamceuticals.
Brimdin	Rasco Pharma
Cantil	Helicon Pharmaceutek Pakistan (Pvt) Ltd.
Capcid	Olive Laboratories
Concid	Reko Pharmacal (Pvt) Ltd.
Curofam	Mega Pharmaceuticals (Pvt) Ltd
Delfamo-Z	Delta Pharma (Pvt) Ltd.
Dewrel Dispersible	English Pharmaceuticals Industries
Ducid	Glaxosmithkline
Duonol	Euro Pharma International
Efrel	English Pharmaceuticals Industries
Epidine	Zinta Pharmaceuticals Industries
Facid	Shafaz Pharma International (Pvt) Ltd.
Fadiphine	Global Pharmaceuticals
Fagastril	Gray`S Pharmaceuticals
Famace	Medera Pharmaceuticals (Pvt) Ltd.
Famcet	Friends Pharma (Pvt) Ltd
Famcidine	Webros Pharmaceuticals
Famdin	Pakistan Pharmaceutical Products (Pvt) Ltd.
Famid	Wilshire Laboratories (Pvt) Ltd.
Famitine	Efroze Chemical Industries (Pvt) Ltd.
Famobex	Cibex (Private) Limited
Famocin	Navegal Laboratories
Famodine	Neutro Pharma (Pvt) Ltd.
Famogem	Delux Chemical Industries
Famogen	Genera Pharmaceuticals
Famonon	Dr. Raza Pharma (Private) Limited
Famopep	Royal Consumer Manufacturing Company
Famopsin	High - Q International
Famorax	Mediceena Pharma (Pvt) Ltd.
Famorjine	Adfa San Pharmaceuticals.
Famosaf	Saaaf Pharmaceuticals
Famoscot	Scotmann Pharmaceuticals
Famosib	Irza Pharma (Pvt) Ltd.
Famosure	Medisure Laboratories Pakistan (Pvt.) Ltd.
Famot-40	Shaigan Pharmaceuticals (Pvt) Ltd
Famotid	Amson Vaccines & Pharma (Pvt) Ltd.
Famotop	Xenon Pharmaceuticals (Pvt) Ltd.
Famowan	Nawan Laboratories (Pvt) Ltd.
Famron	P.D.H. Pharmaceuticals (Pvt) Ltd.
Famtab	Zanctok Pharmaceuticals
Famtaza	Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Famtine	Efroze Chemical Industries (Pvt) Ltd.
Famulcer	Swiss Pharmaceuticals (Pvt) Ltd.
Famus	Biogen Pharma
Fanitin	Europak Pharma (Pvt) Ltd
Fapcid	Lexicon Pharmaceuticals (Pvt) Ltd.
Fd 40	Tagma Pharma (Pvt) Ltd.
Feawel	Cherwel Pharmaceuticals (Pvt) Ltd
Fedcid	Fedro Pharmaceutical
Fedohit-40	Unipharma (Pvt) Ltd.
Femas	Pearl Pharmaceuticals
Femme	Batala Pharmaceuticals.
Femoceran	Alina Combine Pharmaceuticals (Pvt) Ltd.
Femodine	Neutro Pharma (Pvt) Ltd.
Fencid	Pharmacare Laboratories (Pvt) Ltd.
Flodin	Flow Pharmaceuticals (Pvt) Ltd.
Flut 40	Zephyr Pharmatec (Pvt) Ltd.
Fm 40	Hizat Pharmaceutical Industries (Pvt) Ltd.
Fogo	Goodman Laboratories
Fomen	Shrooq Pharmaceuticals
Fomicid	Himont Pharmaceuticals (Pvt) Ltd.
Fotel	Ideal Pharmaceutical Industries
Fumota	Orta Labs. (Pvt) Ltd.
Gastapil	Danas Pharmaceuticals (Pvt) Ltd
Gaster	Hamaz Pharmaceutical (Pvt) Ltd.
Gastoch	Usawa Pharmaceuticals
Gastoch	Usawa Pharmaceuticals
Gastridine	Tg Pharma
Gastrodine	Harmann Pharmaceutical Laboratories (Pvt) Ltd.
Gd-Cid	21st Century Pharmaceuticals Co.
Gepep	Akson Pharmaceuticals (Pvt) Ltd.
Gerdin	Global Pharmaceuticals
Gimed	Albro Pharma
H2-Foz	Fozan Pharmaceuticals Industriers (Pvt) Ltd
H2bf	Rakaposhi Pharmaceutical (Pvt) Ltd.
H2bf	Rakaposhi Pharmaceutical (Pvt) Ltd.
H2f	Ferozsons Laboratoies Ltd.
Hepsin	Heal Pharmaceuticals Pvt Ltd
Hiler	Muller & Phipps Pakistan (Pvt) Ltd.
Hodine	Honig Pharmaceuticals Laboratories
Hycocid	Bloom Pharmaceuticals (Pvt) Ltd.
Ispep	Medisure Laboratories Pakistan (Pvt.) Ltd.
Jevity	Wilshire Laboratories (Pvt) Ltd.
Jevity	Wilshire Laboratories (Pvt) Ltd.
Kalfot	Medera Pharmaceuticals (Pvt) Ltd.
Ketacid	Hygeia Pharmaceuticals
Kotidine	Al-Habib Pharmaceuticals.
Litz	Glitz Pharma
Lyofam	Valor Pharmaceuticals
Max-H2	Makson Pharmaceuticals
Mot	Jaens Pharma
Motn	Caraway Pharmaceuticals
Nencid	Nenza Pharmaceuticals (Pvt) Limited
Neofam	Neo Medix
No-Acid	Nova Med Pharmaceuticals
No-Ul	Fynk Pharmaceuticals
Nobar	Caylex Pharmaceuticals (Pvt) Ltd.
Nocer	Bryon Pharmaceuticals (Pvt) Ltd.
Nocid	Novartis Pharma (Pak) Ltd
Nogacid	Lowitt Pharmaceuticals (Pvt) Ltd
Novifam	Novins International
Nutam	Robins Pharmaceutical Industries
Optifam	Merck Private Ltd.
Otofam	Genome Pharmaceuticals (Pvt) Ltd
Panalba	R.Y. International
Pandona	Venture Chemical & Pharmaceuticals (Pvt) Ltd.
Papcinil	Crest Pharmaceuticals
Pepcidine	Obs
Pepcifine	Semos Pharmaceuticals (Pvt) Ltd.
Pepcifine	Semos Pharmaceuticals (Pvt) Ltd.
Pepcimed	Medicraft Pharmaceuticals (Pvt) Ltd.
Pepciron	Mass Pharma (Private) Limited
Pepdine	Lotus Pharmaceuticals (Pvt) Ltd
Pepdis	Candid Pharmaceuticals
Pepfin	Innvotek Pharmaceuticals
Pepgard	Elko Organization (Pvt) Ltd.
Pepgen	Fassgen Pharmaceuticals
Pepmon	Shaheen Agencies
Pepnic	Dosaco Laboratories
Peprid	Helix Pharma (Private) Limited
Peptiban	Werrick Pharmaceuticals
Peptiban Dispersible	Werrick Pharmaceuticals
Peptiloc	Bosch Pharmaceuticals (Pvt) Ltd.
Pepton	Paramount Pharmaceuticals
Pharmotidine	Epharm Laboratories
Pitfam	Jinnah Pharmaceuticals
Placid	Pulse Pharmaceuticals
Polypep	Wilsons Pharmaceuticals
Prilosec	Aries Pharmaceuticals (Pvt) Ltd
Pulfame	Pulse Pharmaceuticals
Qincid	Qintar Pharmacuticals
Quamatel	Medimpex Scientific Office
Qucid-40	Qureshi Pharma (Pvt) Ltd.
R-Cid	Silver Oak Corporation.
Recid	Regent Laboratories Ltd.
Reducid	Platinum Pharmaceuticals (Pvt.) Ltd.
Resid	Regent Laboratories Ltd.
Ricer	Polyfine Chempharma (Pvt) Ltd.
Sac-40	Amass Enterprises
Servibet	Polyfine Chempharma (Pvt) Ltd.
Shaw	Shawan Pharmaceuticals
So-Fem	Roryan Pharmaceutical Industries (Pvt) Ltd
Stomachcare	Jawa Pharmaceuticals(Pvt) Ltd.
Surfac	Meditech Pharmaceuticals
Tabrodine	Tabros Pharma
Tagafam Dispersible	Tagma Pharma (Pvt) Ltd.
Tasofam	F.M. Pharmaceuticals International
Tifam	Drug Pharmaceuticals Chem. (Pvt).
Tinopep	Remington Pharmaceutical Industries (Pvt) Ltd.
Tulip	Tagma Pharma (Pvt) Ltd.
Ul Samark	Vital Mark Liboratories (Pvt) Ltd
Ul-Safe	Saydon Pharmaceutical Industries (Pvt) Ltd.
Ulcare	Z-Jans Pharmaceutical (Pvt) Ltd.
Ulcefame	Zephyr Pharmatec (Pvt) Ltd.
Ulcemal	Atco Laboratories Limited
Ulcenil	Siza International (Pvt) Ltd.
Ulcepep-40	Epoch Pharmaceutical
Ulcerx	Hansel Pharmacueutical Pvt (Ltd)
Ulciban	Star Laboratories (Pvt) Ltd.
Ulcofin	Pharmix Laboratories (Private) Limited.
Ulfam	Highnoon Laboratories Ltd.
Ulfarid	Davis Pharmaceutical Laboratories
Ulsin	Don Valley Pharmaceuticals (Pvt) Ltd.
Vefam	Vega Pharmaceuticals Ltd.
Vie-D	Tagma Pharma (Pvt) Ltd.
Volvic	Rotex Medica Pakistan (Pvt) Ltd
Wisfa	Wise Pharmaceuticals (Pvt) Ltd
Xegerd	Navegal Laboratories
Yamadin	Bex Pharma (Pvt) Ltd.
Zebid	Atco Laboratories Limited
Zepsin	Cirin Pharmaceuticals (Pvt) Ltd.

 

Famotidine Capsules 20 Mg in Pakistan
Kamcid	Bloom Pharmaceuticals (Pvt) Ltd.

 

Famotidine Capsules 40 Mg in Pakistan
Kamcid	Bloom Pharmaceuticals (Pvt) Ltd.
Stolee	Flow Pharmaceuticals (Pvt) Ltd.